AKT1 and prostate neoplasm: The PD activity of AZD5363 was determined by its ability to inhibit the phosphorylation AKT substrates (FOXO1, GSK3β) and downstream pathway biomarkers (4E-BP1 and S6), after a single oral dose in prostate tumor tissue.